Overdiagnosis and overtreatment of breast cancer -: Estimates of overdiagnosis from two trials of mammographic screening for breast cancer

被引:138
作者
Duffy, SW [1 ]
Agbaje, O
Tabar, L
Vitak, B
Bjurstam, N
Björneld, L
Myles, JP
Warwick, J
机构
[1] Univ London, Queen Mary Coll, Wolfson Inst Prevent Med, Canc Res UK Dept Epidemiol Math & Stat, London, England
[2] Falun Cent Hosp, Dept Mammog, Falun, Sweden
[3] Univ Hosp, Dept Radiol, Linkoping, Sweden
[4] Univ Hosp N Norway, Ctr Breast Imaging, Dept Radiol, Tromso, Norway
[5] Sahlgrens Univ Hosp, Dept Radiol, Gothenburg, Sweden
关键词
D O I
10.1186/bcr1354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Randomised controlled trials have shown that the policy of mammographic screening confers a substantial and significant reduction in breast cancer mortality. This has often been accompanied, however, by an increase in breast cancer incidence, particularly during the early years of a screening programme, which has led to concerns about overdiagnosis, that is to say, the diagnosis of disease that, if left undetected and therefore untreated, would not become symptomatic. We used incidence data from two randomised controlled trials of mammographic screening, the Swedish Two-county Trial and the Gothenburg Trial, to establish the timing and magnitude of any excess incidence of invasive disease and ductal carcinoma in situ ( DCIS) in the study groups, to ascertain whether the excess incidence of DCIS reported early in a screening trial is balanced by a later deficit in invasive disease and provide explicit estimates of the rate of 'real' and non-progressive 'overdiagnosed' tumours from the study groups of the trials. We used a multistate model for overdiagnosis and used Markov Chain Monte Carlo methods to estimate the parameters. After taking into account the effect of lead time, we estimated that less than 5% of cases diagnosed at prevalence screen and less than 1% of cases diagnosed at incidence screens are being overdiagnosed. Overall, we estimate overdiagnosis to be around 1% of all cases diagnosed in screened populations. These estimates are, however, subject to considerable uncertainty. Our results suggest that overdiagnosis in mammography screening is a minor phenomenon, but further studies with very large numbers are required for more precise estimation.
引用
收藏
页码:258 / 265
页数:8
相关论文
共 16 条
[1]  
[Anonymous], 2002, BREAST CANC SCREENIN
[2]   Programme sensitivity and effectiveness of mammography service screening in Helsinki, Finland [J].
Anttila, A ;
Koskela, J ;
Hakama, M .
JOURNAL OF MEDICAL SCREENING, 2002, 9 (04) :153-158
[3]   The Gothenburg Breast Screening Trial [J].
Bjurstam, N ;
Björneld, L ;
Warwick, J ;
Sala, E ;
Duffy, SW ;
Nyström, L ;
Walker, N ;
Cahlin, E ;
Eriksson, O ;
Hafström, LO ;
Lingaas, H ;
Mattsson, J ;
Persson, S ;
Rudenstam, CM ;
Salander, H ;
Säve-Söderbergh, J ;
Wahlin, T .
CANCER, 2003, 97 (10) :2387-2396
[4]  
Ernster V L, 1997, J Natl Cancer Inst Monogr, P151
[5]  
Ernster VL, 2002, JNCI-J NATL CANCER I, V94, P1546
[6]   Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? [J].
Evans, AJ ;
Pinder, SE ;
Ellis, IO ;
Wilson, ARM .
JOURNAL OF MEDICAL SCREENING, 2001, 8 (03) :149-151
[7]   Modelling the impact of detecting and treating carcinoma in situ in a breast screening programme [J].
McCann, J ;
Treasure, P ;
Duffy, S .
JOURNAL OF MEDICAL SCREENING, 2004, 11 (03) :117-125
[8]  
Nyström L, 2002, LANCET, V360, P724
[9]   Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? [J].
Paci, E ;
Warwick, J ;
Falini, P ;
Duffy, SW .
JOURNAL OF MEDICAL SCREENING, 2004, 11 (01) :23-27
[10]   The randomized trials of breast cancer screening: what have we learned? [J].
Smith, RA ;
Duffy, SW ;
Gabe, R ;
Tabar, L ;
Yen, AMF ;
Chen, THH .
RADIOLOGIC CLINICS OF NORTH AMERICA, 2004, 42 (05) :793-+